Biological E's Corbevax gets WHO emergency use authorisation

Hyderabad, Jan 16 (IANS) Biological E. Limited (BE), a Hyderabad-based vaccines and pharmaceutical company, on Tuesday announced that the World Health Organisation (WHO) has granted an Emergency Use Listing (EUL) to their Corbevax, which is India's first indigenously developed Covid-19 vaccine that is based on protein sub-unit platform.

Mahima Datla, Managing Director, Biological E. Limited, said that WHO EUL would help them to use the platform to continue developing Covid-19 vaccines as and when it starts impacting public health.

"We are confident that this endorsement from WHO will bolster our global fight against Covid-19," she added.

"We understand that several countries come under a lot of fiscal pressure when it comes to dealing with Covid-19. We aim to reach the people in those countries with Corbevax, just as we have done with all our other vaccines. Our commitment is to provide affordable and accessible vaccines that are of high quality and the WHO EUL lays a path for us to make that possible," she said.

The Drugs Controller General of India (DCGI) already approved Corbevax for restricted use in emergency among adults, adolescents and young children in a sequential manner from December 2021 to April 2022; as well as India's first heterologous Covid-19 booster shot for adults aged 18 years and above in June 2022.

BE supplied 100 million doses of Corbevax to the Indian government, which were then utilised in pan-India immunisation campaigns; mainly in 12 to 14-year-old children.

Datla noted that while several companies which entered the field of vaccine development and manufacturing during the Covid-19 pandemic exited soon afterwards either due to paucity of funds or lack of success, BE continues to remain committed to develop and provide access to high quality affordable vaccines globally.

BE has been working on a next-generation Covid-19 vaccine that is based on the XBB1.5 variant of the SARS-CoV-2 virus, which would conform to WHO TAG-CO-VAC recommendations.

BE's candidate vaccine has completed all required pre-clinical animal studies, which suggest that it will provide adequate protection against the currently circulating variants.

BE has recently received final approval from CDSCO to begin clinical trials of the XBB.1.5 variant vaccine in India. The clinical trials will commence soon at various trial sites in India.

BE already qualified manufacturing infrastructure for producing variant vaccines to initiate supply at a short notice.

The Corbevax vaccine is administered through intramuscular route with two doses scheduled 28 days apart and is stored at a temperature of 2 to 8 degrees Celsius and presented as 0.5 ml (single dose) vial, 5 ml (10 doses) vial and 10 mL (20 doses) vial pack.